2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

9:00AM-11:00AM: Abstract Number: 2694

Inpatient Treatment Variation in New-Onset Systemic Juvenile Idiopathic Arthritis

Pediatric Rheumatology – ePoster III: Systemic JIA, Fever, & Vasculitis

9:00AM-11:00AM: Abstract Number: 1986

Insights into Osteoarthritis Progression by Gene Expression and miRNA Profiling of Mesenchymal Stromal Cells from Medial and Lateral Femoral Condyles

Osteoarthritis & Joint Biology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1947

Integrating Genetic Risk Scores and Pre-Diagnostic Metabolomics to Infer Dysregulated Mechanisms in Rheumatoid Arthritis in Women

Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 1941

Interactions Between Genome-Wide Genetic Factors and Current Smoking in Determining SLE Risk

Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 2031

Interferon Alpha Promotes Caspase-Dependent Apoptosis Independently of Reactive Oxygen Species in Ultraviolet B-Exposed Keratinocytes

SLE – Etiology & Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: L06

Interferon-gamma (IFN-γ) Neutralization with Emapalumab and Time to Response in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (s-JIA) who failed High-Dose Glucocorticoids

Late-Breaking Abstracts ePoster

9:00AM-11:00AM: Abstract Number: 2307

Intermetatarsal Bursitis Is Prevalent in Patients with Established Rheumatoid Arthritis and Is Associated with Anti-CCP and RF

RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2346

Interstitial Lung Abnormalities in Rheumatoid Arthritis Patients: Identifying Associated Risk Factors

RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2298

Interstitial Lung Disease Is Associated with Distinct Fine Specificities of Anti-Carbamylated Peptide/Protein Antibodies in Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2042

Intestinal Microbiota Alters Th1/Th17 Balance but Is Dispensable for the Development of Systemic Autoimmune Disease in BXD2 Mice

SLE – Etiology & Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 2110

Invasive Aspergillosis in Rheumatologic Patients in Tertiary Care Hospital in Mexico

Infection-Related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 1940

Investigating the Post-Partum Flare in Rheumatoid Arthritis Using Transcriptome Analysis

Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 2714

Investigation of Inactive Disease Activity States Among JIA Patients in the CARRA Registry

Pediatric Rheumatology – ePoster III: Systemic JIA, Fever, & Vasculitis

9:00AM-11:00AM: Abstract Number: 2033

IRAK4 Inhibition Suppresses TLR7, TLR9, and SLE Serum-Induced IFNA Production in Primary Human Plasmacytoid Dendritic Cells

SLE – Etiology & Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 2334

Is Cardiovascular Risk and Mortality in Rheumatoid Arthritis Compared to Diabetes Mellitus and the General Population Overestimated?

RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].